Travere Therapeutics (TVTX) Amortizatization of Intangibles (2011 - 2023)
Travere Therapeutics (TVTX) posted Amortizatization of Intangibles of $2.3 million for Q4 2023, up 22.84% on a QoQ basis from $1.9 million in Q3 2023, and up 122.39% year-over-year from $1.0 million in Q4 2022.
Travere Therapeutics (TVTX) Amortizatization of Intangibles (2011 - 2023) Analysis & Trends
Travere Therapeutics' Amortizatization of Intangibles history runs 11 years deep, the most recent figure standing at $2.3 million for Q4 2023.
- Quarterly Amortizatization of Intangibles rose 122.39% year-over-year to $2.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $5.7 million (up 717.43% YoY) and the FY2025 annual result came in at $4.4 million, down 2.18% from the prior year.
- Amortizatization of Intangibles was $2.3 million for Q4 2023 at Travere Therapeutics, up from $1.9 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.3 million in Q4 2023 and bottomed at -$697000.0 in Q4 2021.
- A 5-year average of $161333.3 and a median of -$155500.0 in 2020 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2019 — Amortizatization of Intangibles soared 295.1% — and 2020, when it plunged 2022.22%.
- Travere Therapeutics' Amortizatization of Intangibles stood at $9000.0 in 2019, then plunged by 2022.22% to -$173000.0 in 2020, then slumped by 302.89% to -$697000.0 in 2021, then surged by 246.77% to $1.0 million in 2022, then soared by 122.39% to $2.3 million in 2023.
- Business Quant data shows TVTX's Amortizatization of Intangibles at $2.3 million in Q4 2023, $1.9 million in Q3 2023, and $1.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Travere Therapeutics | 5.24 Bn | 5.24 Bn | 125.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.28 Mn |
| Dec 31, 2023 | 2.28 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 572,000.00 |
| Sep 30, 2022 | 572,000.00 |
| Jun 30, 2022 | -222,000.00 |
| Jun 30, 2022 | -222,000.00 |
| Mar 31, 2022 | -673,000.00 |
| Mar 31, 2022 | -673,000.00 |
| Dec 31, 2021 | -697,000.00 |
| Dec 31, 2021 | -697,000.00 |
| Sep 30, 2021 | -651,000.00 |
| Sep 30, 2021 | -651,000.00 |
| Jun 30, 2021 | -483,000.00 |
| Jun 30, 2021 | -483,000.00 |
| Mar 31, 2021 | -177,000.00 |
| Mar 31, 2021 | -177,000.00 |